of an Antifibrinolytic in Significant Hemorrhage
(CRASH-2) study, in which 20,000 trauma patients
with bleeding or at risk for major bleeding were
randomly assigned to receive either tranexamic
acid or placebo. Patients who received tranexamic
acid within 3 hours after injury had a one-third
reduction in deaths from bleeding.14 After a secondary
analysis of their data, the CRASH-2 investigators
recommended that tranexamic acid
be administered as soon as possible after injury,
since the drug ceased to confer benefit and appeared
to be associated with increased mortality
if it was administered more than 3 hours after
injury.15 Reassuringly for a hemostatic drug, the
incidence of thrombosis after trauma was not
increased in the study patients. Strong evidence
that tranexamic acid reduced the need for blood
transfusion in surgery has been available for
years, although the effect of tranexamic acid on
thromboembolic events and mortality in such
patients remains uncertain.16
of an Antifibrinolytic in Significant Hemorrhage(CRASH-2) study, in which 20,000 trauma patientswith bleeding or at risk for major bleeding wererandomly assigned to receive either tranexamicacid or placebo. Patients who received tranexamicacid within 3 hours after injury had a one-thirdreduction in deaths from bleeding.14 After a secondaryanalysis of their data, the CRASH-2 investigatorsrecommended that tranexamic acidbe administered as soon as possible after injury,since the drug ceased to confer benefit and appearedto be associated with increased mortalityif it was administered more than 3 hours afterinjury.15 Reassuringly for a hemostatic drug, theincidence of thrombosis after trauma was notincreased in the study patients. Strong evidencethat tranexamic acid reduced the need for bloodtransfusion in surgery has been available foryears, although the effect of tranexamic acid onthromboembolic events and mortality in suchpatients remains uncertain.16
การแปล กรุณารอสักครู่..